ArticleMicrobial cell factories2026
Combinatorial optimization engineering for the high-level production of shikimic acid in Escherichia coli.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Shikimic acid is a crucial precursor for the production of indole derivatives and chiral drugs, and the biomanufacturing offers reduced cost and simplified process compared to traditional plant extraction. Current research on industrial-scale production of shikimic acid achieves notable progress, yet the limitations associated with high production cost, complex operation process, and excessive byproduct formation still persist. To tackle these difficulties, this study aimed at establishing a high-efficient shikimic acid-producer through systematic modification and fermentation optimization in Escherichia coli. First, the route for the synthesis of shikimic acid was divided into three modules (i.e., sugar uptake, bioproduct synthesis, and metabolite catabolism), of which the disruption of glucose uptake system, reinforcement of bioproduct synthesis, and block of its catabolism rewired metabolic fluxes and provided the possibility for efficient synthesis. Next, series of systematic engineering involving in deleting pyruvate bypass, reinforcing the pentose phosphate (PP) pathway, and adjusting promoter strength promoted precursor supply and avoided metabolic overflow. The best strain EC022 generated 5.27 g/L of shikimic acid, highlighting the significance of precursor availability. Then, fermentation conditions including substrate concentration, inoculation size, cultivation temperature, induction time, and C/N ratio were comprehensively optimized, which boosted the bioproduction to 8.70 g/L in the optimized conditions. Finally, a final titer of 61.87 g/L shikimic acid was achieved in a 7 L bioreactor. This study developed an efficient shikimic acid-producer with industrial potential through metabolic engineering and bioprocess optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.